Point72 Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Point72 Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$94.6K	Buy	25,427 +9,771	+62%	+$67.5K	﹤0.01%	3617
2025 Q4	$128K	Buy	+15,656	New	+$116K	﹤0.01%	3709
2023 Q1	–	Sell	-141,446	Closed	-$917K	–	2409
2022 Q4	$917K	Sell	141,446 -44,758	-24%	-$369K	﹤0.01%	1063
2022 Q3	$1.66M	Sell	186,204 -17,496	-9%	-$178K	0.01%	965
2022 Q2	$2.03M	Sell	203,700 -57,856	-22%	-$573K	0.01%	933
2022 Q1	$3.03M	Buy	261,556 +84,537	+48%	+$941K	0.01%	805
2021 Q4	$1.97M	Buy	+177,019	New	+$1.72M	0.01%	825

Other funds holding LFCR

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's LFCR Position: Q1 2026 in Review

Point72 Asset Management increased its Lifecore Biomedical (LFCR) stake by 62% in Q1 2026, buying an estimated $67.5K and bringing the position to 25,427 shares worth $94.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3617.

Point72 Asset Management first reported a position in LFCR in Q4 2021 and has held it in 7 quarters since. The position peaked at $3.03M in Q1 2022. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

Point72 Asset Management held 25,427 shares of Lifecore Biomedical worth $94.6K as of Q1 2026.
Point72 Asset Management bought 9,771 Lifecore Biomedical shares in Q1 2026, an estimated $67.5K.
Lifecore Biomedical made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3617 holding.
Point72 Asset Management first reported a position in Lifecore Biomedical in Q4 2021 and has held it in 7 quarters since.
Point72 Asset Management's Lifecore Biomedical position peaked at $3.03M in Q1 2022.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.